



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

Dated: 31 Jan, 2020

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India  
Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

## **Shilpa Medicare Limited Launches Lenvatinib mesylate under the brand name Lenshil® in India**

Shilpa receives approval for lenvatinib mesylate capsules for patients with treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma in India

Shilpa will commercialize the product under the brand name Lenshil® to become the first Indian company in the country to bring the cheaper version of this drug to Indian cancer patients. Now Indian patients will get access to this breakthrough therapy at an affordable cost and manufactured in India. The presently available brand of lenvatinib mesylate in market is being imported into India.

Shilpa Medicare Ltd., a research-led global integrated pharmaceutical company, today announced that the company has received regulatory approval to market a lenvatinib mesylate a breakthrough therapy for the treatment of patients with differentiated thyroid cancer (DTC) and hepatocellular carcinoma. This marks the approval of first Indian brand of lenvatinib mesylate fully manufactured in India.

Shilpa received regulatory approval for Lenvatinib 4 mg and 10 mg capsules, after successfully showing bioequivalence to Lenvima, a brand of Lenvatinib mesylate capsules marketed by Eisai.

The approved dosage strengths are up to 24 mg of lenvatinib alone or combined with other drugs according to the condition being treated.

# Shilpa Medicare Limited



Innovating for  
affordable healthcare

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

CIN No. L85110KA1987PLC008739

E-mail : [info@vbsilpa.com](mailto:info@vbsilpa.com) Website : [www.vbsilpa.com](http://www.vbsilpa.com)

The company shall launch lenvatinib, at a breakthrough price which is over 50% lower than the existing brand available in India. Prior to the launch of Lenshil®, the average therapy cost of Originator lenvatinib in India was about Rs.1.90 lacs.

About Lenvatinib mesylate: Lenvatinib is an anti-cancer drug for the treatment of certain kinds of cancers including thyroid and hepatocellular, and potentially for other cancers (renal & endometrium) as well. Lenvatinib is a member of the class of quinolones, an oral multikinase inhibitor that inhibits vascular endothelial growth factor (VEGF) receptors (VEGFR 1-3), fibroblast growth factor (FGF) receptors (FGFR1-4), platelet-derived growth factor (PDGF) receptor  $\alpha$ , KIT, and RET. First approved in 2015 by US FDA for thyroid cancer, in 2018 Lenvatinib capsules was approved as a first-line therapeutic option for the treatment of patients with unresectable hepatocellular carcinoma (HCC). It is expected that lenvatinib will be approved for many other cancers in coming years.

About Shilpa Medicare Limited, Shilpa Medicare Ltd. is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 100 Pharma & Biotech companies in India. Shilpa is a pioneering player in the manufacture of oncological APIs and formulations.

Shilpa has several molecules in various stages of development in the oncology segment and is planning to bring a few oncology drugs as cheaper versions for first-time in India.

Shilpa has manufacturing facilities for APIs and formulations and have four R&D centers. The Generics business of Shilpa caters to the requirements of the US, Europe and other emerging markets apart from India. Shilpa supplies its APIs to over 20 countries, including the US, various countries in the EU, South America and India.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

**VISHNUKANTH C CHITLADA**  
Managing Director

